(Circulation. 2001;104:2256.)
© 2001 American Heart Association, Inc.
Editorials |
The Time Has Come to Stop Letting the HERS Tale Wag the Dogma
From the Molecular Cardiology Research Institute, the Department of Medicine, and the Division of Cardiology, New England Medical Center Hospitals and Tufts University School of Medicine, Boston, Mass.
Correspondence to Michael E. Mendelsohn, MD, Tufts University School of Medicine, New England Medical Center, Molecular Cardiology Research Institute, 750 Washington St, Box 80, Boston, MA 02111. E-mail mmendelsohn@lifespan.org
Key Words: Editorials • hormones • women • risk factors • trials
The premise of this commentary is simple. We believe there has been enormous overinterpretation and misinterpretation of recent clinical data (the HERS tale1) with regard to the efficacy of hormone replacement therapy (HRT) in preventing or diminishing the risk of heart disease (the dogma). Both the medical and lay press have focused on obtaining a single yes-or-no answer to the question, "Does postmenopausal HRT reduce the risk of cardiovascular disease (CVD)?" This oversimplified approach has led to unjustified generalizations with regard to the question and to the summary judgment in some circles that HRT is not beneficial for the prevention of heart disease.
See p 2300
A brief review of the literature in this area reveals the source of much of the controversy and confusion. In 1992, an elegant meta-analysis by Grady and colleagues2 concluded that "there is extensive and consistent observational evidence that estrogen use reduces risks for CHD [coronary heart disease] about 35%." This conclusion has since been supported by additional observational studies that together include several hundred thousand woman-years of follow-up. As one example, a recent update from the Nurse’s Health Study (>400 000 woman-years of follow-up) again confirmed a 40% to 60% reduction in cardiovascular events in women taking HRT.3,4 In contrast to this large body of observational data, the recent prospective Heart Estrogen/progestin Replacement Study (HERS) proved negative. HERS, the first prospective, randomized trial of HRT assessing cardiovascular end points, demonstrated that combined HRT (0.625 mg/d conjugated equine estrogens [CEE] and 2.5 mg/d of
This article has been cited by other articles:
 |
|
 |
|
  J. D. Gardner, G. L. Brower, T. G. Voloshenyuk, and J. S. Janicki Cardioprotection in female rats subjected to chronic volume overload: synergistic interaction of estrogen and phytoestrogens Am J Physiol Heart Circ Physiol, January 1, 2008; 294(1): H198 - H204. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. A. Babiker, D. Lips, R. Meyer, E. Delvaux, P. Zandberg, B. Janssen, G. van Eys, C. Grohe, and P. A. Doevendans Estrogen Receptor {beta} Protects the Murine Heart Against Left Ventricular Hypertrophy Arterioscler Thromb Vasc Biol, July 1, 2006; 26(7): 1524 - 1530. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. K. Koh and B.-K. Yoon Controversies regarding hormone therapy: Insights from inflammation and hemostasis Cardiovasc Res, April 1, 2006; 70(1): 22 - 30. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Iwakura, S. Shastry, C. Luedemann, H. Hamada, A. Kawamoto, R. Kishore, Y. Zhu, G. Qin, M. Silver, T. Thorne, et al. Estradiol Enhances Recovery After Myocardial Infarction by Augmenting Incorporation of Bone Marrow-Derived Endothelial Progenitor Cells Into Sites of Ischemia-Induced Neovascularization via Endothelial Nitric Oxide Synthase-Mediated Activation of Matrix Metalloproteinase-9 Circulation, March 28, 2006; 113(12): 1605 - 1614. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Mendelsohn and R. H. Karas Molecular and Cellular Basis of Cardiovascular Gender Differences Science, June 10, 2005; 308(5728): 1583 - 1587. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. K. Koh and I. Sakuma Should Progestins Be Blamed for the Failure of Hormone Replacement Therapy to Reduce Cardiovascular Events in Randomized Controlled Trials? Arterioscler Thromb Vasc Biol, July 1, 2004; 24(7): 1171 - 1179. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. N. Hodis, W. J. Mack, R. A. Lobo, D. M. Herrington, T. D. Howard, B. Brosnihan, G. A. Hawkins, D. M. Reboussin, J. Xu, S. L. Zheng, et al. Randomized Controlled Trial Evidence That Estrogen Replacement Therapy Reduces the Progression of Subclinical Atherosclerosis in Healthy Postmenopausal Women Without Preexisting Cardiovascular Disease * Response Circulation, July 8, 2003; 108 (1): e5 - e5. [Full Text] [PDF]
|
|
|
|
 |
|
 M. van Eickels, R. D. Patten, M. J. Aronovitz, A. Alsheikh-Ali, K. Gostyla, F. Celestin, C. Grohe, M. E. Mendelsohn, and R. H. Karas 17-Beta-Estradiol increases cardiac remodeling and mortality in mice with myocardial infarction J. Am. Coll. Cardiol., June 4, 2003; 41(11): 2084 - 2092. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Herrington Hormone Replacement Therapy and Heart Disease: Replacing Dogma With Data Circulation, January 7, 2003; 107(1): 2 - 4. [Full Text] [PDF]
|
|
|
|
 |
|
 N. A. Nussmeier, M. R. Marino, and W. K. Vaughn Hormone replacement therapy is associated with improved survival in women undergoing coronary artery bypass grafting J. Thorac. Cardiovasc. Surg., December 1, 2002; 124(6): 1225 - 1229. [Abstract] [Full Text]
|
|
|
|
 |
|
 K. L. Chambliss and P. W. Shaul Estrogen Modulation of Endothelial Nitric Oxide Synthase Endocr. Rev., October 1, 2002; 23(5): 665 - 686. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. K. Koh Effects of estrogen on the vascular wall: vasomotor function and inflammation Cardiovasc Res, September 1, 2002; 55(4): 714 - 726. [Full Text] [PDF]
|
|
|
|
 |
|
 W. L. Isley Growth Hormone Therapy for Adults: Not Ready for Prime Time? Ann Intern Med, August 6, 2002; 137(3): 190 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. J. Benjamin and E. Christians Exercise, Estrogen, and Ischemic Cardioprotection by Heat Shock Protein 70 Circ. Res., May 3, 2002; 90(8): 833 - 835. [Full Text] [PDF]
|
|